ArticleCureus2025
Breast Mass Revealing Hidden Lung Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the second most common cancer and the leading cause of cancer-related deaths in the United States, frequently metastasizing to the brain, bones, liver, and adrenal glands. However, it is uncommon for lung malignancies to metastasize to the breast, and is generally assumed to carry a poor prognosis. We present the case of a 62-year-old female who presented for an annual physical exam and complained of persistent neck pain without neurological deficit. A screening mammogram revealed a 0.4 cm right breast mass. A biopsy of the mass showed carcinoma with micropapillary features. Immunohistochemistry was positive for cytokeratin (CK) 7 and thyroid transcription factor 1 (TTF-1)and negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), indicating a primary lung origin. Next-generation sequencing (NGS) was negative for a targetable mutation. The patient was treated for metastatic lung adenocarcinoma with carboplatin, pemetrexed, and pembrolizumab for 4 cycles followed by maintenance with pemetrexed and pembrolizumab. Per response evaluation criteria in solid tumors (RECIST) the patient continues to have stable disease. Imaging and immunohistochemistry (IHC) are critical in differentiating between primary and metastatic lesions. Additionally, using phylogenetic analysis to understand tumor evolution allows for valuable insights into how metastases develop and spread, thus assisting in personalized treatment strategies. Early and accurate diagnosis is essential for appropriate treatment planning leading to improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.